Cellectis to Present Promising Clinical Data for Lasme-cel and Eti-cel at EHA 2026 Congress
CLLS has more than doubled off its 52-week low of $1.327.
Summary
Cellectis announced it will present promising clinical data for its CAR-T candidates, lasme-cel and eti-cel, at the upcoming EHA 2026 Annual Congress, highlighting progress towards pivotal trials.
Key Events · Product Development and Regulatory · CLLS
-
Oral Presentation for Lasme-cel
Full Phase 1 data from the BALLI-01 trial for lasme-cel (CD22-directed allogeneic CAR-T) in heavily pretreated patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) will be presented. The data highlights promising safety and response rates and forms the basis for the ongoing pivotal Phase 2 program, with interim data expected in Q4 2026.
-
Poster Presentation for Eti-cel
Preliminary analysis from the Phase 1 NATHALI-01 study for eti-cel (CD20/CD22 allogeneic CAR-T) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) will be presented, providing early mechanistic insights. Phase 1 clinical data is planned for disclosure in Q4 2026.
Analysis · CLLS · Life Sciences
Cellectis will present full Phase 1 data for its lead CAR-T candidate, lasme-cel, at the European Hematology Association (EHA) congress. This data, showing promising safety and response rates, forms the basis for a pivotal Phase 2 program, which is a critical step towards potential regulatory approval. The company will also present preliminary data for eti-cel.
At the time of this filing, CLLS was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $287.9M. The 52-week trading range was $1.33 to $5.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.